Free Trial

Maze Therapeutics (MAZE) Competitors

Maze Therapeutics logo
$16.45 -1.19 (-6.75%)
As of 04:00 PM Eastern

MAZE vs. MOR, ALVO, CPRX, MIRM, ARWR, RARE, AMRX, OGN, GMTX, and IBRX

Should you be buying Maze Therapeutics stock or one of its competitors? The main competitors of Maze Therapeutics include MorphoSys (MOR), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), Mirum Pharmaceuticals (MIRM), Arrowhead Pharmaceuticals (ARWR), Ultragenyx Pharmaceutical (RARE), Amneal Pharmaceuticals (AMRX), Organon & Co. (OGN), Gemini Therapeutics (GMTX), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.

Maze Therapeutics vs. Its Competitors

Maze Therapeutics (NASDAQ:MAZE) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

18.4% of MorphoSys shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Maze Therapeutics has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Maze Therapeutics' return on equity of 0.00% beat MorphoSys' return on equity.

Company Net Margins Return on Equity Return on Assets
Maze TherapeuticsN/A N/A N/A
MorphoSys -226.79%-694.31%-22.55%

In the previous week, Maze Therapeutics had 9 more articles in the media than MorphoSys. MarketBeat recorded 9 mentions for Maze Therapeutics and 0 mentions for MorphoSys. Maze Therapeutics' average media sentiment score of 0.38 beat MorphoSys' score of 0.00 indicating that Maze Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Maze Therapeutics Neutral
MorphoSys Neutral

Maze Therapeutics currently has a consensus target price of $25.60, indicating a potential upside of 55.62%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Maze Therapeutics is more favorable than MorphoSys.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maze Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.29
MorphoSys
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Maze Therapeutics has higher earnings, but lower revenue than MorphoSys.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maze Therapeutics$167.50M4.30$52.23MN/AN/A
MorphoSys$238.28M11.99-$205.35M-$3.48-5.45

Summary

Maze Therapeutics beats MorphoSys on 10 of the 14 factors compared between the two stocks.

Get Maze Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MAZE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MAZE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MAZE vs. The Competition

MetricMaze TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$772.58M$3.06B$5.70B$9.48B
Dividend YieldN/A2.37%4.59%3.99%
P/E RatioN/A20.7327.9019.95
Price / Sales4.30321.07442.18102.66
Price / Cash115.2243.2336.5558.97
Price / Book-2.318.308.635.90
Net Income$52.23M-$55.19M$3.24B$258.42M
7 Day Performance-3.58%5.07%3.22%1.94%
1 Month Performance59.24%17.61%10.72%12.02%
1 Year PerformanceN/A7.03%34.94%20.81%

Maze Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MAZE
Maze Therapeutics
N/A$16.45
-6.7%
$25.60
+55.6%
N/A$772.58M$167.50M0.00121News Coverage
Analyst Forecast
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
ALVO
Alvotech
2.8765 of 5 stars
$8.63
-1.1%
$16.00
+85.4%
-22.4%$2.63B$491.98M23.321,032
CPRX
Catalyst Pharmaceuticals
4.9134 of 5 stars
$21.03
-2.0%
$32.83
+56.1%
+22.8%$2.62B$534.65M13.3980News Coverage
Positive News
MIRM
Mirum Pharmaceuticals
3.9526 of 5 stars
$51.93
-1.5%
$65.50
+26.1%
+32.0%$2.61B$336.89M-32.25140
ARWR
Arrowhead Pharmaceuticals
3.879 of 5 stars
$16.76
-11.1%
$43.71
+160.8%
-44.7%$2.60B$3.55M-11.97400
RARE
Ultragenyx Pharmaceutical
4.3469 of 5 stars
$26.31
-4.0%
$83.64
+217.9%
-38.0%$2.59B$590.69M-4.471,294Upcoming Earnings
Gap Down
High Trading Volume
AMRX
Amneal Pharmaceuticals
3.2894 of 5 stars
$7.97
-3.3%
$11.60
+45.5%
+8.6%$2.58B$2.83B-199.208,100
OGN
Organon & Co.
4.7622 of 5 stars
$9.46
-1.9%
$18.00
+90.3%
-53.0%$2.51B$6.40B3.284,000
GMTX
Gemini Therapeutics
N/A$57.77
0.0%
N/A+32.2%$2.50BN/A-57.7730High Trading Volume
IBRX
ImmunityBio
2.0236 of 5 stars
$2.75
-2.8%
$12.25
+345.5%
-47.1%$2.50B$14.74M-4.74590

Related Companies and Tools


This page (NASDAQ:MAZE) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners